Artículo
Glycans pave the way for immunotherapy in triple-negative breast cancer
Fecha de publicación:
02/2018
Editorial:
Cell Press
Revista:
Cancer Cell
ISSN:
1535-6108
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment. The clinical efficacy of therapies targeting the PD-1/PD-L1 pathway is still limited. In this issue of Cancer Cell, Li and colleagues identify a PD-L1 glycosylation-based mechanism in triple-negative breast cancer that fosters immunosuppression by enhancing interactions with PD-1. Targeting glycosylated PD-L1 with a drug-conjugated antibody opens new avenues for treatment.
Palabras clave:
GLYCANS
,
BREAST CANCER
,
CANCER
,
POLYSACCHARIDES
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(IBYME)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Articulos de INST.DE BIOLOGIA Y MEDICINA EXPERIMENTAL (I)
Citación
Girotti, Maria Romina; Salatino, Mariana; Rabinovich, Gabriel Adrián; Glycans pave the way for immunotherapy in triple-negative breast cancer; Cell Press; Cancer Cell; 33; 2; 2-2018; 155-157
Compartir
Altmétricas